Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.
An epigenetic blood test can now track cancer recurrence in all neuroblastoma patients, regardless of their tumor's genetic mutations.
This study demonstrates that epigenetic profiling of cell-free DNA provides a universal, mutation-independent approach for monitoring minimal residual disease and recurrence in high-risk neuroblastoma, validated in pediatric patient samples. Unlike mutation-dependent ctDNA monitoring, this epigenetic approach works for all patients, addressing a critical surveillance gap in pediatric oncology.
What the study was
- Study design
- Translational study with prospective sample collection
- Population
- Children with high-risk neuroblastoma
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Clinical cancer research
Why it surfaced
Clin Cancer Res; mutation-agnostic epigenetic liquid biopsy for neuroblastoma is genuinely novel; overcomes mutation-dependency limitation; pediatric rare disease with high unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.